Germany: Medical Cannabis Market Overview 2025

Germany remains Europe’s largest medical cannabis market, serving as both a regulatory model and commercial hub for the continent. Following the enactment of the Medical Cannabis Act (MedCanG) on 1 April 2024, Germany removed cannabis from its Narcotics Act (BtMG), dramatically reducing bureaucracy and triggering record levels of market expansion.

The estimated medical cannabis market size for 2025 exceeds €670 million, with forecasts projecting growth to over €XXX million by 2029 (Prohibition Partners Market Sizing Forecasts, 2025–2029).

The MedCanG reform has simplified production, prescribing, and distribution processes, enabling rapid scaling of patient access, particularly through telemedicine platforms. While the market remains largely import-driven, domestic cultivation is expanding under new authorisation rules that have replaced the previous tender system.

Germany’s well-developed supply chain of importers, distributors, pharmacies, and digital clinics positions it as the centre of gravity for European cannabis commerce, influencing regulatory development across the EU.

The Cannabis Act (CanG), incorporating MedCanG, took effect on 1 April 2024, introducing wide-ranging reforms:

Officials have indicated that the framework will undergo a review in Q4 2025, potentially introducing tighter oversight of telemedicine clinics and online prescriptions, mirroring approaches adopted in other EU markets.oice.ed by the European Medicines Agency, such as Sativex, which remains available under a restricted prescription pathway.

Who Can Prescribe? All licensed physicians in Germany are authorised to prescribe medical cannabis.

Publicly Insured Patients Patients covered by statutory health insurance (SHI) are eligible for reimbursement if all of the following criteria are met:

Privately Insured Patients Private prescriptions are permitted when clinically justified for a specific indication; approval from insurers is typically faster and less restrictive.

Telemedicine Expansion The combination of e-prescriptions and the removal of narcotic classification has enabled rapid growth of telemedicine clinics.

Leading platforms include DoktorABC, DrAnsay, and Green Medical, which report accelerating patient onboarding since Q2 2024.toring conducted through hospital networks.ad patient access, though reimbursement and bureaucratic complexity often limit uptake.

Over 20 platforms now operate nationwide.

The top five providers attract more than 150,000 monthly visitors each, according to June 2025 data.

Germany continues to offer Europe’s widest range of medical cannabis products, primarily flower, with growing availability of extracts and vapour formulations.

Import Share (2025):

50% of products remain imported from:

Emerging suppliers (2024–25): Argentina, Czech Republic, Zimbabwe, New Zealand, United Kingdom.

Product Portfolio Highlights:

Ilios Santae – first vape extract (68 % THC, launched 2023)

Remexian – broadest Canadian portfolio

Tilray (Portugal) – largest Portuguese supplier

Demecan (Germany) – leading domestic producer

Germany remains Europe’s primary import destination for medical cannabis.

Import Trends:

Top Suppliers (2025):

Exports remain limited, primarily research-based or pilot-scale shipments coordinated through BfArM.

Before 2024, domestic cultivation was constrained by strict government tenders, capped at 2,600 kg per year, supplied by Tilray/Aphria, Aurora, and Demecan.

Post-MedCanG, these tender restrictions were abolished, enabling market-driven licensing and expansion.

Estimated 2025 Production Capacity:

Although domestic cultivation remains modest relative to import volumes, increased flexibility and private investment are expected to gradually diversify supply and stabilise pricing.

Germany’s medical cannabis market is entering a phase of maturity and integration. The MedCanG framework has removed structural barriers, improved efficiency, and attracted international capital.

Key trends shaping 2025 and beyond include:

Germany remains Europe’s benchmark medical cannabis market, combining regulatory sophistication, market scale, and commercial opportunity unmatched elsewhere on the continent.

Get granular market sizing forecasts, patient population data, and competitive intelligence across 31 European markets. Trusted by investors, operators, and regulators across the continent.